Genervon to present at the American Society for Experimental Neurotherapeutics (ASENT) 2019 Global Healthcare Conference

March 3, 2019

Genervon Biopharmaceuticals is scheduled to present again this year at the ASENT 2019 Annual Meeting and Global Healthcare Conference on Neurotherapeutics in Maryland on March 28. Genervon will be presenting its published papers…

Read More >


Genervon Biopharmaceuticals to Present Its Neurodegeneration Platform at WuXi Healthcare CEO Roundtable 2019

March 3, 2019

SHANGHAI, CHINA — Genervon will present its neurodegeneration therapeutic treatments platform at the 2019 WuXi Healthcare Forum CEO Roundtable on March 5 at the St. Regis Hotel, Shanghai, showcasing the cutting edge of Genervon’s R&D and clinical stage drug pipelines….

健能万生化制药企业(Genervon Biopharmaceuticals) 在三月五日在中国上海靜安瑞吉酒店2019 药明康德健康产业论坛CEO圆桌环节,展示健能万的创新产品,技术,成果和风釆。。。

Read More >


GM6 Attenuates Alzheimer's Disease Pathology in APP Mice

March 2, 2019

“GM6 Attenuates Alzheimer's Disease Pathology in APP Mice” has been published online by Molecular Neurobiology on 2/23/2019 (PMID number 30798443). The paper concludes, “Application of GM6…

Read More >


GENERVON PRESENTED ITS GM604 MECHANISMS OF ACTION AT THE 29TH INTERNATIONAL SYMPOSIUM ON ALS/MND IN GLASGOW, UK

March 1, 2019

Genervon Biopharmaceuticals presented its GM604 Mechanisms of Action at the 29th International Symposium on ALS/MND held on Dec. 8-9, 2018 in Glasgow, UK. The paper was published in Translational Neurodegeneration at the same time. The full published paper text can be found…. 

Read More >